$FBRX News

Barclays Downgrades Forte Biosciences to Equal-Weight, Raises Price Target to $77

Should You Be Bullish on Forte Biosciences (FBRX)?

Barclays Initiates Coverage On Forte Biosciences with Overweight Rating, Announces Price Target of $74

Forte Biosciences, Inc. (FBRX) Discusses Positive Results From FB102 Phase 1b Vitiligo Study and Mechanism of Action - Slideshow

Forte Biosciences' FB102 Hits Key Goal in Vitiligo Study, Shows Durable Improvement

Forte Biosciences: FB102 Is Becoming A Platform Story, Not A Single-Indication Bet

Forte Biosciences shares surge after positive phase 1b vitiligo results

FBRX Stock On Track For Biggest Single-Day Gains In 20 Months – What’s Behind The Super Rally?

Forte Biosciences Skin Pigmentation Disorder Drug Shows Strong Efficacy, Safety In Early Study

Forte Biosciences, Inc. (FBRX) Discusses Positive Results From FB102 Phase 1b Vitiligo Study and Mechanism of Action Transcript

Forte Biosciences Shares Climb After Positive Phase 1b Vitiligo Trial Results (FBRX)

Forte Biosciences Skin Pigmentation Disorder Drug Shows Strong Efficacy, Safety In Early Study

FB102 Achieves Statistically Significant Improvement in Vitiligo at Week 24 After Completion of 12-Week Treatment Period

Forte Biosciences Reports Results From FB102 Double-Blind Placebo-Controlled Phase 1b Study In Vitiligo

One Forte Biosciences Insider Raised Stake By 30% In Previous Year

Forte Biosciences Files $500M Shelf Registration For Potential Issuance Of Common Stock, Preferred Stock, Debt Securities, Warrants, And Other Securities From Time To Time

Forte Biosciences Q1 EPS $(1.24) Misses $(1.19) Estimate

Forte Biosciences: Stunning Bull Run Could Continue Thanks To Near-Term Data Readouts

Forte Biosciences shares are trading higher. The company announced the pricing of its $150 million offering of 5.7 million shares at 26.27 per share.

Forte Biosciences shares are trading higher. The company announced the pricing of its $150 million offering of 5.7 million shares at 26.27 per share.